Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to support basic research, discovery, and/or preclinical development of highly efficacious vaccines for malaria and potentially other mosquito-borne illness. The program will encourage novel approaches to vaccine design that capitalize on recent technological innovations including structure-based immunogen design, and/or combination vaccines to reduce parasite infection and/or reduce malaria disease burden. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Details

• Agency: National Institutes of Health
• Department: Department of Health and Human Services
• Opportunity #: RFA-AI-28-024
• Instrument: grant

Eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).